Literature DB >> 3402229

Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods.

T R Franson1, E J Quebbeman, J Whipple, R Thomson, J Bubrick, S L Rosenberger, R K Ausman.   

Abstract

Aminoglycoside (gentamicin, tobramycin) dosage regimens and subsequent serum concentrations were compared in 30 patients treated initially using traditional physician-determined methods and then switched to a pharmacokinetic-based treatment program. Patients received more drug during the kinetic phase (median 5 mg/kg) than during the traditional phase (median 3.6 mg/kg) and achieved greater peak serum concentration (5.9 vs. 4.4 micrograms/ml). Seventy-three percent of kinetic peak values but only 27% of traditional peak values exceeded 5.0 micrograms/ml. Trough concentrations were comparable in both phases of study and no nephrotoxicity was observed. This pharmacokinetic-based management program achieved more consistently greater therapeutic peak concentrations and provided more individualized therapy than did physicians. The use of pharmacokinetic consultants may be of benefit in administering safely optimal aminoglycoside therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402229     DOI: 10.1097/00003246-198809000-00004

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  11 in total

Review 1.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 2.  Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

Authors:  M H Ensom; G A Davis; C D Cropp; R J Ensom
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

3.  Population pharmacokinetics of amikacin in critically ill patients.

Authors:  F Bressolle; A Gouby; J M Martinez; P Joubert; G Saissi; R Guillaud; R Gomeni
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.

Authors:  F Konrad; R Wagner; B Neumeister; H Rommel; M Georgieff
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 5.  An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

6.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 7.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

8.  Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Authors:  D P Nicolau; C D Freeman; P P Belliveau; C H Nightingale; J W Ross; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

9.  Practical computer-assisted dosing for aminoglycoside antibiotics.

Authors:  L A Lenert; H Klostermann; R W Coleman; J Lurie; T F Blaschke
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 10.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.